Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
MannKind Makes Big Workforce Cuts
by Ann M. Thayer
February 21, 2011
| A version of this story appeared in
Volume 89, Issue 8
Facing an uncertain regulatory path for its inhaled insulin product Afrezza, MannKind Corp. has cut about 41% of its workforce, or 178 employees. With guidance from FDA, the company will focus on securing approval of the drug, according to CEO Alfred Mann, who is the firm’s largest investor. MannKind has also canceled a supply contract for recombinant human insulin with Organon, which is now a Merck & Co. subsidiary. In 2010, MannKind had no revenues and a net loss of $171 million, largely from spending on the clinical development of Afrezza.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter